A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：EUROPEAN JOURNAL OF CANCER ISSN： 0959-8049 版本： SCI-CDE 出版频率： Semi-monthly 出版社： ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB   出版社网址： http://www.elsevier.com/wps/find/homepage.cws_home 期刊网址： http://www.elsevier.com/wps/find/journaldescription.cws_home/104/description 影响因子： 9.162 主题范畴： ONCOLOGY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal   The European Journal of Cancer (including EJC Supplements), is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention. Letters that comment on an article previously published in the EJC are also welcomed. Official Journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European School of Oncology (ESO), the European Association for Cancer Research (EACR), the Federation of European Cancer Societies (FECS) and the European Society of Mastology (EUSOMA). Supplements to the European Journal of Cancer are published under the title EJC Supplements (ISSN 1359-6349). All subscribers to European Journal of Cancer automatically receive this publication.   Instructions to Authors   The European Journal of Cancer is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention. Letters that comment on an article previously published in the EJC are also welcomed. All published papers containing research data are subject to peer-review. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Submitting the Manuscript Authors should submit two copies of the manuscript with two sets of figures (all copies of photomicrographs and gels should be of good quality) together with an electronic copy (full details of electronic submission can be obtained from http://www.authors.elsevier.com Figures should not be imported into the text file. Full details for the electronic submission of artwork can be obtained from http://www.authors.elsevier.com) to: Editorial Office, European Journal of Cancer, Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK. (Tel: +44 (0)1865 843282; fax: +44 (0)1865 843977; e-mail: suzanne.peedell@ejcancer.com/emma.cannell@ejcancer.com) In a covering letter, please identify the person responsible for editorial correspondence (address, telephone and fax numbers, and e-mail address). The covering letter must be signed by the corresponding author on behalf of all the authors. Also include details of any previous or concurrent submission. It is also useful to give any information for the Editor-in-Chief to support the submission (e.g. original or confirmatory data, relevance, topicality) or whether any text, figures, or tables can be omitted. Authors should suggest up to 5 reviewers. These suggestions may not always be used. Receipt of all contributions is acknowledged immediately, with a reference number for enquiries. EJC is not responsible for the loss of manuscripts. Authors should keep a copy of the manuscript. EJC does not return rejected manuscripts. One copy and all glossy artwork are stored for a month after the rejection date before disposal. Authors should submit an electronic copy of their paper with the final version of the manuscript. The electronic copy should match the hard copy exactly. Randomised controlled trials All randomised controlled trials submitted for publication in EJC should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org/statement.html for more information. Ethics For clinical trials, details of ethical committee approval and the type of informed consent should be stated. Patients' and volunteers' names, initials, and hospital numbers should not be used. Conflict of interest At the end of the text, under a subheading "Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Role of the funding source All sources of funding should be declared as an acknowledgement at the end of the text. Previous publication No substantial part of the manuscript may have been or may be published elsewhere. This restriction does not apply to abstracts or press reports published in connection with scientific meetings. For advice on previous or simultaneous publication, contact the Editorial Office. Format Write in English with double line-spacing on one side of single A4 sheets with high-quality print. Limits on lengths are: Papers up to 3000 words, abstract up to 150 words, up to 30 references Letters up to 500 words, up to 10 references, 1 table/figure As a rule, there are about 250 words on an A4 page of double line-spaced typing. EJC will consider manuscripts prepared according to the Vancouver guidelines (Uniform requirements for manuscripts submitted to biomedical numbers, N Engl J Med 1991, 324, 424-428). Authors are advised to read these guidelines, especially when deciding on who qualifies as an author. Authors may also find useful: Guidelines for writing papers, Br Med J 1991, 302, 40-42. Manuscripts may be altered to meet EJC style. Manuscripts containing research data, generally follow the order: Introduction, Patients (or Materials) and Methods, Results, and Discussion. Start each section at the top of a new page, and number all the pages. Title page: The title page should include a concise but informative title; the authors' names; the department/institution and an address for each author, with a symbol to link authors and their addresses; the name, address, fax and telephone numbers and e-mail address of the author to whom correspondence should be addressed; details of sources of support in the form of grants, equipment, and drugs. Abstract: The second page should start with the abstract, which should be up to maximum of 150 words and must include the aim of the study, a brief summary of the methods, results and a concluding statement. Keywords: Include up to 10 key words from the Medical Subject Headings from Index Medicus Text: This should start on the third page and should be divided into the following sections: Introduction, Patients (or Materials) and Methods, Results, and Discussion. References: references should be listed on a new page. They should be consecutively in parentheses in the text. 'Unpublished data' and 'Personal communications' are not allowed. As an alternative, say in the text, for example, '(data not shown)' or '(Dr F.G. Tomlin, Karolinska Institute)'. Accepted but unpublished papers (but not submitted manuscripts) can be referenced as 'in press'. The format of references should be that of the Vancouver guidelines. Include: The names of all the authors when six or fewer, followed by their initials. Otherwise list only the first three and add et al The title of the article or chapter The journal name abbreviated as in Index Medicus, the year and volume, and the first and last pages For a book, the names of any editors (as for authors), the city and name of the publisher, and the year and pages Examples for an article in a journal (1) or book (2) or for a book (3) would be: 1. Jiang FN, Liu DJ, Neyndorff H, Chester M, Jiang S-Y, Luy JG. Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J Natl Cancer Inst 1991, 83, 1218-1225. 2. Gullick WJ, Venter DJ. The c-erbB2 and its expression in human tumours. In Waxman J, Sikora K, eds. The Molecular Biology of Cancer. Oxford, Blackwell Scientific Publications, 1989, 38-53. 3. Lumley JSP, Green CJ, Lear P, Angell-James JE, Essentials of Experimental Surgery. London, Butterworths,1990. Figures: figures should be cited consecutively in the text. All figures should be original glossy photographs or professional drawings (high quality computer-generated artwork is acceptable). Please do not frame the figures. Mark the back of each figure with its number and the first author's name, and indicate the top of the figure. Figures are generally reduced to 84 mm wide or less when published. Type the legends in order on a separate page; limit the legend to 40 words or less. Full details for the electronic submission of artwork can be obtained from http://www.authors.elsevier.com. Colour Illustrations:If, together with your accepted article, you submit usable colour figures when Elsevier Science will ensure, at no additional charge, that these figures will appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding the costs from Elsevier Science after receipt of your accepted article. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/locate/authorartwork. Please note: Because of technical complications which can arise by converting colour figures to "grey scale" (for the printed version should you not opt for colour in print) please submit in addition usable black and white prints corresponding to all the colour illustrations. Tables: tables should be cited consecutively in the text. Type tables on separate pages with a title. Avoid white spaces in the table by using footnotes, and ensure all symbols or abbreviation are explained. Take care to distinguish between 'zero' and 'not done' as an entry in the table. Abbreviations and units. Generally, avoid abbreviations in the Title and abbreviating single words. Otherwise explain all abbreviations at first mention in the Abstract and text, except for: DNA, RNA, AIDS, and HIV. Standard SI abbreviations for units do not need to be spelt out. Drug names. Use generic names for drugs. Commercial names may be included in parentheses at first mention in the text. Complicated drug names or regimens may be abbreviated, with the abbreviation in parentheses after first mention. Copyright All authors must sign the 'Transfer of Copyright' agreement before the article can be published. This transfer agreement enables Elsevier Science Ltd to protect the copyright material for the authors, but does not relinquish the author's proprietary rights. The copyright transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microfilm or the right to adapt the article for use in conjunction with computer systems and programmes, including reproduction or publication in machine-readable form and incorporation in retrieval systems. If excerpts (for example figures) from copyrighted works are included the author is responsible for obtaining written permission from the copyright holder prior to submitting the final version of the paper. Full credit must be given to such sources. Proofs Proofs on PDF format will be sent to the corresponding author via e-mail and should be returned within 48 hours of receipt. It is therefore essential to provide the full e-mail addresses of the corresponding author. Keep a copy of corrected proofs. Corrections should be restricted to typesetting errors as any substantial changes other than these may be charged to the author. The responsibility of detecting errors is with the author. Fifty offprints will be supplied free of charge. Further offprints and copies of the issue can be ordered at a specially reduced rate using the order form sent to the corresponding author by the Publisher. Author enquiries Visit the Author Gateway from Elsevier Science http://authors.elsevier.com for the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed. The Author Gateway also provides detailed artwork guidelines, copyright information, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication. Editorial Board   Editor-in-Chief John Smyth, Cancer Research UK, Edinburgh Oncology Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR Editor: (Clinical Oncology) Jaap Verweij, Department of Medical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands John Kurtz, Radiation Oncology, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland Editor: (Experimental Oncology) Maurizio D'Incalci, Department of Oncology, Istituto di Ricerche Farmacologiche 'Mario Negri', Via Eritrea, 62, 20157, Milan, Italy John Kurtz, Radiation Oncology, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland Editors: (Breast Cancer) Roger Blamey, Consultant Surgeon, Heathfield House, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK John Kurtz, Radiation Oncology, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland Editor (Epidemiology and Prevention) John Kurtz, Radiation Oncology, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland Jan Willem Coebergh, Department of Public Health, Erasmus University Medical Centre, PO Box 1738, NL-3000 DR Rotterdam, The Netherlands Editor: (Paediatric Oncology) John Kurtz, Radiation Oncology, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland Jon Pritchard, Honorary Senior Lecturer at University of Edinburgh, Consultant Paediatric Oncologist, Royal Hospital for Sick Children, 9 Sciennes Road, Lothian, Edinburgh, EH9 1LF, UK Editorial Office (EJC):  European Journal of Cancer, Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK Scientific Editor: Emma Cannell, Oxford, UK Administrative Editor (all sections except experimental oncology): Suzanne Peedell, Oxford, UK Administrative Editor (experimental oncology): Ruth Beer, Oxford, UK Paediatric Oncology Panel: E. Bouffet, Canada H.N. Caron, The Netherlands F. Gibson, UK D.M. Green, USA J.L. Habrand, France A. Hall, UK G. Henze, Germany M. Kaneko, Japan S.J. Kellie, Australia R.K. Marwaha, India M. Michelagnoli, UK D.R. Newell, UK J. Plaschkes, Switzerland K. Pritchard-Jones, UK C.A. Stiller, UK H.P. Wagner, Switzerland H.B. Wallace, UK R.B. Womer, USA B. de Camargo, Brazil Editorial Consultants: M. Aapro, Switzerland P. Allavena, Italy J.P. Armand, France F. Balkwill, UK H. Bartelink, The Netherlands M. Baum, UK M. Bolla, France P. Boyle, Italy A.M. Burger, Canada G.P. Canellos, USA A. Carbone, Italy J. Cassidy, Scotland M. Castiglione, Switzerland L. Cataliotti, Italy J. Collard, The Netherlands R. Colomer, Spain H. Cortes-Funes, Spain A. Costa, Italy D. Cunningham, UK J. Cuzick, UK Y.A. De Clerck, USA M.J.A. De Jonge, The Netherlands C. Dittrich, Austria A.M.M. Eggermont, The Netherlands I.S. Fentiman, UK T.S. Ganesan, UK E. Garattini, Italy G. Gasparini, Italy K. Geboes, Belgium G. Giaccone, The Netherlands L. Gianni, Italy R. Giavazzi, Italy D. Green, USA P. Greenwald, USA I.R. Hart, UK C. Henderson, USA J.-C. Horiot, France C. Huber, Germany R. Jakesz, Austria J. Jassem, Poland V.C. Jordan, USA S.B. Kaye, UK W.N. Keith, Scotland L.R. Kelland, UK P. Kleihues, France J.M. Kurtz, Switzerland F. Levi, Switzerland H. Ludwig, Austria J. Lunec, UK P. Maguire, UK R. Mertelsmann, Germany F. Meunier, Belgium J.-L. Misset, France H. Mouridsen, Denmark D. Newell, UK L. Norton, USA J. Overgaard, Denmark N. Pavlidis, Greece P. Pelicci, Italy G.J. Peters, The Netherlands P. Price, UK K. Pritchard-Jones, UK D. Raghavan, USA G. Ries, Switzerland J. Ringash, Canada J. Robert, France E. Salminen, Finland R. Sauer, Germany P.M. Schlag, Germany H.-J. Schmoll, Germany C. Sessa, Switzerland P. Sonneveld, The Netherlands C.A. Stiller, UK I. Tannock, Canada E. Van Cutsem, Belgium M. Van Glabbeke, Belgium A. Van Oosterom, Belgium U. Veronesi, Italy J. Wagstaff, UK W.H.B. Wallace, UK J. Whelan, UK R.B. Womer, USA P. Workman, UK J. Zalcberg, Australia H. Zwierzina, Austria